A diverse group of sophisticated investors participated in the round, with a mix of family office, venture capital, and individuals dedicated to the company's mission: Principal investors include Pierre and David Lamond; Corey Goodman, PhD, Managing Partner of venBio and Board Chairman for MindRhythm; DCVC; Aestus Capital; Perseverance Capital Management; Blue Fog Capital; Franklin Berger, Managing Director at FMB Research and Kyle York, CEO and managing partner of York IE.

MindRhythm is a medical technology company focused on preventing neurological injury primarily caused by strokes. Founded by world-renowned experts with significant commercialization experience, MindRhythm's monitoring devices provide novel and real-time visibility to life-threatening situations prehospital allowing clinicians to intervene and prevent brain damage. Collaborating with the healthcare community, MindRhythm looks to apply the same systematic approach to reducing time to treatment in strokes that has been successfully implemented for heart attacks with the STEMI protocol.